JP2007535471A5 - - Google Patents

Download PDF

Info

Publication number
JP2007535471A5
JP2007535471A5 JP2006509122A JP2006509122A JP2007535471A5 JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5 JP 2006509122 A JP2006509122 A JP 2006509122A JP 2006509122 A JP2006509122 A JP 2006509122A JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5
Authority
JP
Japan
Prior art keywords
antibody
binds
library
cll
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535471A (ja
Filing date
Publication date
Priority claimed from US10/379,151 external-priority patent/US7435412B2/en
Priority claimed from US10/736,188 external-priority patent/US20040198661A1/en
Application filed filed Critical
Publication of JP2007535471A publication Critical patent/JP2007535471A/ja
Publication of JP2007535471A5 publication Critical patent/JP2007535471A5/ja
Pending legal-status Critical Current

Links

JP2006509122A 2003-03-04 2004-03-04 慢性リンパ性白血病細胞由来のポリペプチド及び抗体並びにそれらの関連する適用 Pending JP2007535471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/379,151 2003-03-04
US10/379,151 US7435412B2 (en) 2000-12-08 2003-03-04 Chronic lymphocytic leukemia cell line
US10/736,188 2003-12-15
US10/736,188 US20040198661A1 (en) 2000-12-08 2003-12-15 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
PCT/US2004/006577 WO2004078938A2 (en) 2003-03-04 2004-03-04 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2007535471A JP2007535471A (ja) 2007-12-06
JP2007535471A5 true JP2007535471A5 (enExample) 2008-01-24

Family

ID=32965320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509122A Pending JP2007535471A (ja) 2003-03-04 2004-03-04 慢性リンパ性白血病細胞由来のポリペプチド及び抗体並びにそれらの関連する適用

Country Status (6)

Country Link
US (1) US20040198661A1 (enExample)
EP (1) EP1606388A4 (enExample)
JP (1) JP2007535471A (enExample)
KR (1) KR20050108381A (enExample)
CA (1) CA2517968A1 (enExample)
WO (1) WO2004078938A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059280A2 (en) * 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) * 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
AU2002334997A1 (en) * 2001-10-12 2003-04-22 Schering Corporation Use of bispecific antibodies to regulate immune responses
AU2012211347B9 (en) * 2004-07-20 2015-06-18 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
NZ599035A (en) * 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
CA2674578A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
ES2721753T3 (es) 2007-05-21 2019-08-05 Alderbio Holdings Llc Anticuerpos contra IL-6 y usos de los mismos
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CA2694121C (en) * 2007-07-25 2016-06-07 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
JP5620918B2 (ja) * 2008-11-25 2014-11-05 ブリストル・マイヤーズ スクイブ カンパニー アルブミンを上昇および／またはｃｒｐを低下させるためのｉｌ−６アンタゴニスト
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
AU2010296058A1 (en) * 2009-09-16 2012-05-03 Duke University HIV-1 antibodies
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2523976B1 (en) 2010-01-11 2018-04-25 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
MX2012009321A (es) 2010-02-11 2012-11-21 Alexion Pharma Inc Metodos terapeuticos que utilizan anticuerpos anti-cd200.
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
JP6150734B2 (ja) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) * 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) * 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992009690A2 (en) * 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5780279A (en) * 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
DK0606217T4 (da) * 1991-06-27 2009-03-30 Bristol Myers Squibb Co CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
US5508717A (en) * 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
US6011138A (en) * 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
DK1032662T3 (da) * 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US6955811B2 (en) * 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
EP1263786A2 (en) * 2000-03-17 2002-12-11 Reginald M. Gorczynski Methods and compositions for immunoregulation
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
US20030017491A1 (en) * 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
AU2333802A (en) * 2000-11-22 2002-06-03 Transplantation Technologies I Truncated cd200
WO2002059280A2 (en) * 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200

Similar Documents

Publication Publication Date Title
JP2007535471A5 (enExample)
CN102639564B (zh) 抗-cmet抗体及其用于癌症的检测和诊断的用途
JP2019116474A5 (enExample)
JP4280803B2 (ja) 慢性リンパ性白血病細胞株および抗体を産生するためのその使用
JP6180931B2 (ja) 癌の診断および／または予後のための新規な抗体
JP2009517057A5 (enExample)
JP2020522513A5 (enExample)
CN103827144B (zh) 新的抗cxcr4抗体及其用于检测和诊断癌症的用途
JP2013506428A5 (enExample)
JP2012176953A5 (enExample)
WO2006020266A2 (en) Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
JP7245358B2 (ja) 抗ｃｄ２５抗体及びその適用
JP2019512207A5 (enExample)
WO2013017562A1 (en) Use of the antibody i-3859 for the detection and diagnosis of cancer
JP2022058881A (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
CA3009768A1 (en) Compositions and methods for assessing the risk of cancer occurrence
US12091457B2 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
JPWO2019175885A5 (enExample)
JP2020515286A5 (enExample)
US20240117042A1 (en) Immunohistochemistry methods and kir3dl2-specific reagents
JP2021516989A5 (enExample)
JP2024043214A5 (enExample)
US20230192900A1 (en) Bispecific antibodies binding hvem and cd9
JP2021530247A (ja) 癌の診断のためのＢＣｌ−２抗体とイムノアッセイ
NZ749138A (en) Monoclonal antibodies, compositions and methods for detecting mucin -like protein (mlp) as a biomarker for ovarian and pancreatic cancer